Paget’s disease of bone: emphasis on treatment with zoledronic acid

References

• Cundy T, Bolland M. Paget disease of bone. Trends Endocrinol. Metab.19(7), 246–253 (2008).
   PubMedGoogle Scholar
• Ralston SH, Langston AL, Reid IR. Pathogenesis and management of Paget’s disease of bone. Lancet372(9633), 155–163 (2008).
   PubMed Web of Science ®Google Scholar
• Hocking LJ, Lucas GJ, Daroszewska A et al. Domain-specific mutations in sequestosome 1 (SQSTM1) cause familial and sporadic Paget’s disease. Hum. Mol. Genet.11(22), 2735–2739 (2002).
   PubMed Web of Science ®Google Scholar
• Xu J, Wu HF, Ang ES et al. NF-κB modulators in osteolytic bone diseases. Cytokine Growth Factor Rev.20(1), 7–17 (2009).
   PubMed Web of Science ®Google Scholar
• Martini G, Gennari L, Merlotti D et al. Serum OPG and RANKL levels before and after intravenous bisphosphonate treatment in Paget’s disease of bone. Bone40(2), 457–463 (2007).
   PubMed Web of Science ®Google Scholar
• Polyzos SA, Anastasilakis AD, Efstathiadou Z et al. The effect of zoledronic acid on serum dickkopf-1, osteoprotegerin and RANKL in patients with Paget’s disease of bone. Horm. Metab. Res. DOI: 10.1055/s-0029–1233491 (2009) (Epub ahead of print).
   Google Scholar
• Alvarez L, Peris P, Guanabens N et al. Serum osteoprotegerin and its ligand in Paget’s disease of bone: relationship to disease activity and effect of treatment with bisphosphonates. Arthritis Rheum.48(3), 824–828 (2003).
   PubMed Web of Science ®Google Scholar
• Mossetti G, Rendina D, De FG et al. Interleukin-6 and osteoprotegerin systems in Paget’s disease of bone: relationship to risedronate treatment. Bone36(3), 549–554 (2005).
   PubMed Web of Science ®Google Scholar
• Naot D, Bava U, Matthews B et al. Differential gene expression in cultured osteoblasts and bone marrow stromal cells from patients with Paget’s disease of bone. J. Bone Miner. Res.22(2), 298–309 (2007).
   PubMed Web of Science ®Google Scholar
• Marshall MJ, Evans SF, Sharp CA, Powell DE, McCarthy HS, Davie MW. Increased circulating Dickkopf-1 in Paget’s disease of bone. Clin. Biochem.42(10–11), 965–969 (2009).
   PubMed Web of Science ®Google Scholar
• Cooper C, Harvey NC, Dennison EM, van Staa TP. Update on the epidemiology of Paget’s disease of bone. J. Bone Miner. Res.21(Suppl. 2), 3–8 (2006).
   PubMed Web of Science ®Google Scholar
• Cundy T. Is the prevalence of Paget’s disease of bone decreasing? J. Bone Miner. Res.21(Suppl. 2), 9–13 (2006).
   Google Scholar
• Bolland MJ, Tong PC, Naot D et al. Delayed development of Paget’s disease in offspring inheriting SQSTM1 mutations. J. Bone Miner. Res.22(3), 411–415 (2007).
   PubMed Web of Science ®Google Scholar
• Walsh JP, Attewell R, Stuckey BG et al. Treatment of Paget’s disease of bone: a survey of clinical practice in Australia. Bone42(6), 1219–1225 (2008).
   PubMedGoogle Scholar
• Wermers RA, Tiegs RD, Atkinson EJ, Achenbach SJ, Melton LJ 3rd. Morbidity and mortality associated with Paget’s disease of bone: a population-based study. J. Bone Miner. Res.23(6), 819–825 (2008).
   PubMedGoogle Scholar
• Langston AL, Campbell MK, Fraser WD, Maclennan G, Selby P, Ralston SH. Clinical determinants of quality of life in Paget’s disease of bone. Calcif. Tissue Int.80(1), 1–9 (2007).
   PubMed Web of Science ®Google Scholar
• Reid IR, Davidson JS, Wattie D et al. Comparative responses of bone turnover markers to bisphosphonate therapy in Paget’s disease of bone. Bone35(1), 224–230 (2004).
   PubMed Web of Science ®Google Scholar
• Shankar S, Hosking DJ. Biochemical assessment of Paget’s disease of bone. J. Bone Miner. Res.21(Suppl. 2), 22–27 (2006).
   Google Scholar
• Devogelaer JP, Bergmann P, Body JJ et al. Management of patients with Paget’s disease: a consensus document of the Belgian Bone Club. Osteoporos. Int.19(8), 1109–1117 (2008).
   PubMedGoogle Scholar
• Deftos LJ. Treatment of Paget’s disease-taming the wild osteoclast. N. Engl. J. Med.353(9), 872–875 (2005).
   PubMed Web of Science ®Google Scholar
• Siris ES, Lyles KW, Singer FR, Meunier PJ. Medical management of Paget’s disease of bone: indications for treatment and review of current therapies. J. Bone Miner. Res.21(Suppl.), 294–298 (2006).
   Google Scholar
• Colina M, La CR, De LF, Trotta F. Paget’s disease of bone: a review. Rheumatol. Int.28(11), 1069–1075 (2008).
   PubMed Web of Science ®Google Scholar
• Widler L, Jaeggi KA, Glatt M et al. Highly potent geminal bisphosphonates: from pamidronate disodium (Aredia) to zoledronic acid (Zometa). J. Med. Chem.45(17), 3721–3738 (2002).
   PubMed Web of Science ®Google Scholar
• Russell RG. Bisphosphonates: from bench to bedside. Ann. NY Acad. Sci.1068(1), 367–401 (2006).
   PubMed Web of Science ®Google Scholar
• Kimmel DB. Mechanism of action, pharmacokinetic and pharmacodynamic profile, and clinical applications of nitrogen-containing bisphosphonates. J. Dent. Res.86(11), 1022–1033 (2007).
   PubMed Web of Science ®Google Scholar
• Altman RD, Johnston CC, Khairi MR, Wellman H, Serafini AN, Sankey RR. Influence of disodium etidronate on clinical and laboratory manifestations of Paget’s disease of bone (osteitis deformans). N. Engl. J. Med.289(26), 1379–1384 (1973).
   PubMed Web of Science ®Google Scholar
• Dunford JE, Thompson K, Coxon FP et al. Structure–activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates. J. Pharmacol. Exp. Ther.296(2), 235–242 (2001).
   PubMed Web of Science ®Google Scholar
• Nancollas GH, Tang R, Phipps RJ et al. Novel insights into actions of bisphosphonates on bone: differences in interactions with hydroxyapatite. Bone38(5), 617–627 (2006).
   PubMed Web of Science ®Google Scholar
• Reid IR, Miller P, Lyles K et al. Comparison of a single infusion of zoledronic acid with risedronate for Paget’s disease. N. Engl. J. Med.353(9), 898–908 (2005).
   PubMed Web of Science ®Google Scholar
• AACE Ad Hoc Task Force. American Association of Clinical Endocrinologists protocol for standardized production of clinical practice guidelines. Endocr. Pract.10(4), 353–361 (2004).
   Google Scholar
• Arden-Cordone M, Siris ES, Lyles KW et al. Antiresorptive effect of a single infusion of microgram quantities of zoledronate in Paget’s disease of bone. Calcif. Tissue Int.60(5), 415–418 (1997).
   PubMed Web of Science ®Google Scholar
• Garnero P, Gineyts E, Schaffer AV, Seaman J, Delmas PD. Measurement of urinary excretion of nonisomerized and β-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zoledronate in Paget’s disease. Arthritis Rheum.41(2), 354–360 (1998).
   PubMed Web of Science ®Google Scholar
• Buckler H, Fraser W, Hosking D et al. Single infusion of zoledronate in Paget’s disease of bone: a placebo-controlled, dose-ranging study. Bone24(Suppl. 5), 81–85 (1999).
   PubMed Web of Science ®Google Scholar
• Garnero P, Christgau S, Delmas PD. The bisphosphonate zoledronate decreases type II collagen breakdown in patients with Paget’s disease of bone. Bone28(5), 461–464 (2001).
   PubMed Web of Science ®Google Scholar
• Jarrett SJ, Conaghan PG, Sloan VS et al. Preliminary evidence for a structural benefit of the new bisphosphonate zoledronic acid in early rheumatoid arthritis. Arthritis Rheum.54(5), 1410–1414 (2006).
   PubMed Web of Science ®Google Scholar
• Hosking D, Lyles K, Brown JP et al. Long-term control of bone turnover in Paget’s disease with zoledronic acid and risedronate. J. Bone Miner. Res.22(1), 142–148 (2007).
   PubMed Web of Science ®Google Scholar
• Patel S, Stone MD, Coupland C, Hosking DJ. Determinants of remission of Paget’s disease of bone. J. Bone Miner. Res.8(12), 1467–1473 (1993).
   PubMed Web of Science ®Google Scholar
• Merlotti D, Gennari L, Martini G et al. Comparison of different intravenous bisphosphonate regimens for Paget’s disease of bone. J. Bone Miner. Res.22(10), 1510–1517 (2007).
   PubMed Web of Science ®Google Scholar
• Avramidis A, Polyzos SA, Moralidis E et al. Scintigraphic, biochemical, and clinical response to zoledronic acid treatment in patients with Paget’s disease of bone. J. Bone Miner. Metab.26(6), 635–641 (2008).
   PubMedGoogle Scholar
• Chung G, Keen RW. Zoledronate treatment in active Paget’s disease. Ann. Rheum. Dis.62(3), 275–276 (2003).
   PubMedGoogle Scholar
• Tziomalos K, Florentin M, Krikis N, Perifanis V, Karagiannis A, Harsoulis F. Persistent effect of zoledronic acid in Paget’s disease. Clin. Exp. Rheumatol.25(3), 464–466 (2007).
   PubMedGoogle Scholar
• Tucci JR. Therapy with zoledronic acid, 5 mg, for a patient with Paget disease of bone. Endocr. Pract.14(5), 607–610 (2008).
   PubMedGoogle Scholar
• Morton A. Pagetic hydrocephalus treated with zoledronate. Ann. Rheum. Dis.64(9), 1386 (2005).
   PubMedGoogle Scholar
• Pane A. Paget disease manifesting with compressive sixth-nerve palsy that resolved with intravenous zoledronic acid therapy. Arch. Ophthalmol.125(10), 1440–1441 (2007).
   PubMedGoogle Scholar
• Oikonomou A, Birbilis T, Gymnopoulou E, Prassopoulos P. Paget disease of the spine manifested by thoracic and lumbar epidural lipomatosis: magnetic resonance imaging findings. Spine32(25), 789–792 (2007).
   Google Scholar
• Polyzos SA, Anastasilakis AD, Terpos E. Transient secondary hyperparathyroidism following intravenous infusion of zoledronic acid. Support. Care Cancer DOI: 10.1007/s00520-009-0704-0705 (2009) (Epub ahead of print).
   Google Scholar
• Shane E, Goldring S, Christakos S et al. Osteonecrosis of the jaw: more research needed. J. Bone Miner. Res.21(10), 1503–1505 (2006).
   PubMed Web of Science ®Google Scholar
• Bamias A, Kastritis E, Bamia C et al. Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J. Clin. Oncol.23(34), 8580–8587 (2005).
   PubMed Web of Science ®Google Scholar
• Ruggiero SL, Mehrotra B, Rosenberg TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. J. Oral Maxillofac. Surg.62(5), 527–534 (2004).
   PubMed Web of Science ®Google Scholar
• Gueiros LA, Lopes MA, Leao JC. Paget’s disease and bisphosphonate-associated osteonecrosis of the jaws. J. Oral Maxillofac. Surg.66(6), 1319- (2008).
   PubMedGoogle Scholar
• Farrugia MC, Summerlin DJ, Krowiak E et al. Osteonecrosis of the mandible or maxilla associated with the use of new generation bisphosphonates. Laryngoscope116(1), 115–120 (2006).
   PubMed Web of Science ®Google Scholar
• Hay KD, Bishop PA. Association of osteonecrosis of the jaws and bisphosphonate pharmacotherapy: dental implications. N. Z. Dent. J.102(1), 4–9 (2006).
   PubMedGoogle Scholar
• Terpos E, Sezer O, Croucher PI et al. The use of bisphosphonates in multiple myeloma: recommendations of an expert panel on behalf of the European Myeloma Network. Ann. Oncol.20(8), 1303–1317 (2009).
   PubMed Web of Science ®Google Scholar
• Labinson P, Taxel P. Multiple fractures in a woman receiving 24 years of etidronate treatment for Paget’s disease. Conn. Med.71(5), 269–273 (2007).
   PubMedGoogle Scholar
• Boyce BF, Adamson BB, Gallacher SJ, Byars J, Ralston SH, Boyle IT. Mineralisation defects after pamidronate for Paget’s disease. Lancet343(8907), 1231–1232 (1994).
   PubMed Web of Science ®Google Scholar
• Chang JT, Green L, Beitz J. Renal failure with the use of zoledronic acid. N. Engl. J. Med.349(17), 1676–1679 (2003).
   PubMed Web of Science ®Google Scholar
• Black DM, Delmas PD, Eastell R et al. Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N. Engl. J. Med.356(18), 1809–1822 (2007).
   PubMed Web of Science ®Google Scholar
• Fromigue O, Body JJ. Bisphosphonates influence the proliferation and the maturation of normal human osteoblasts. J. Endocrinol. Invest25(6), 539–546 (2002).
   PubMed Web of Science ®Google Scholar
• Reinholz GG, Getz B, Pederson L et al. Bisphosphonates directly regulate cell proliferation, differentiation, and gene expression in human osteoblasts. Cancer Res.60(21), 6001–6007 (2000).
   PubMed Web of Science ®Google Scholar
• Ebert R, Zeck S, Krug R et al. Pulse treatment with zoledronic acid causes sustained commitment of bone marrow derived mesenchymal stem cells for osteogenic differentiation. Bone44(5), 858–864 (2009).
   PubMed Web of Science ®Google Scholar
• Fujita K, Janz S. Attenuation of WNT signaling by DKK-1 and -2 regulates BMP2-induced osteoblast differentiation and expression of OPG, RANKL and M-CSF. Mol. Cancer6, 71 (2007).
   PubMed Web of Science ®Google Scholar
• Krishnan V, Bryant HU, Macdougald OA. Regulation of bone mass by Wnt signaling. J. Clin. Invest.116(5), 1202–1209 (2006).
   PubMed Web of Science ®Google Scholar
• Canalis E, Giustina A, Bilezikian JP. Mechanisms of anabolic therapies for osteoporosis. N. Engl. J. Med.357(9), 905–916 (2007).
   PubMed Web of Science ®Google Scholar
• Tenta R, Pitulis N, Tiblalexi D et al. Mechanisms of the action of zoledronic acid on human MG-63 osteosarcoma cells. Horm. Metab. Res.40(11), 737–745 (2008).
   PubMed Web of Science ®Google Scholar
• Dass CR, Choong PF. Zoledronic acid inhibits osteosarcoma growth in an orthotopic model. Mol. Cancer Ther.6(12), 3263–3270 (2007).
   PubMed Web of Science ®Google Scholar
• Labrinidis A, Hay S, Liapis V, Ponomarev V, Findlay DM, Evdokiou A. Zoledronic acid inhibits both the osteolytic and osteoblastic components of osteosarcoma lesions in a mouse model. Clin. Cancer Res.15(10), 3451–3461 (2009).
   PubMed Web of Science ®Google Scholar